Skip to content

Shares (Diluted) at other companies

CTO
Citius Oncology, Inc.CTOR
100M+39.8%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
15.6M+0.8%
Corvus Pharmaceuticals logo
Corvus PharmaceuticalsCRVS
90M+19.8%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
1B+20.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
20.1M+91.2%
Janux Therapeutics logo
Janux TherapeuticsJANX
62.7M+1.4%

Other financials

Income statement

See full
Revenue-
Net income-$7.5M-13.1%
EPS (diluted)-$0.13+13.3%

Balance sheet

See full
Cash & equivalents$6.3M+1.3%
Total debt$456.9K+178%
Total equity$23.2M+135%
Total assets$29.7M+103%

Cash flow

See full
Operating cash flow-$4.4M+6.9%
CapEx$48.8K+14.5%
Free cash flow-$4.5M+6.7%

Valuation

See full
Market cap$155.39M+45.8%
Enterprise value$149.54M+52.3%

Returns & leverage

See full
Return on equity-187.2%
Debt / equity0.0×
Current ratio1.2×-1.8×

Where this comes from

Reported directly by TuHURA Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The official record: TuHURA Biosciences, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about TuHURA Biosciences, Inc.'s shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TuHURA Biosciences, Inc.'s shares (diluted)?
TuHURA Biosciences, Inc. (HURA) reported shares (diluted) of 60M in Q1 2026.
How has TuHURA Biosciences, Inc.'s shares (diluted) changed year-over-year?
TuHURA Biosciences, Inc.'s shares (diluted) increased by 38.3% year-over-year, from 43.4M to 60M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.